Home Multaq

In a recent FDA sponsored study, Multaq, or dronedarone, was found to increase chances of death, stroke, or other serious cardiovascular issues by 200% compared to patients not on the antiarrhythmic drug. Multaq is widely used with patients with permanent atrial fibrillation or atrial flutter.

This study, referred to the FDA as PALLAS, was stopped early due to the severe negative results. Although this study is considered preliminary,  the FDA does recommend that, "patients taking Multaq should talk to their healthcare professional about whether they should continue to take Multaq for non-permanent atrial fibrillation."

 
Have You Been Injured?
Free Claim Review
If you or a loved one have suffered a serious injury or side effect related to drug or supplement, please contact us for a free and confidential case review.
 

 

 

 

 

 

 

 

 



 

 

 

 

 

  
 
 
Polls
Do You Think The FDA Is Doing Enough To Protect Consumers?
 
Facebook MySpace Twitter Digg Delicious Stumbleupon Google Bookmarks RSS Feed